GC Biopharma expands ALYGLO safety evidence amid growing US immunoglobulin sales
GC Biopharma will present expanded aggregation testing across 18 lots of five IVIG products and a new review of ALYGLO Phase 3 safety data. The analyses identify measurable molecular differences and provide additional safety context, but neither establishes comparative clinical superiority.